Legend Biotech (LEGN) has released an update.
Legend Biotech Corporation, a leader in cell therapy, has announced a preliminary adjusted net loss of approximately $94.7 to $109.7 million for the first half of 2024. These unaudited figures represent the company’s performance up to June 30, 2024, and are subject to change pending completion of financial procedures. The full financial results will be made available on August 9, 2024, giving investors insight into the company’s mid-year fiscal standing.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
